MYO5A::FGFR1represents a novel fusion event in pediatric low-grade glioma
Open Access
- 1 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 5 (1) , vdad017
Abstract
Robert T Galvin, MD, Cynthia Zheng, Garrett Fitzpatrick, MD, Colleen L Forster, Carolina Sandoval-Garcia, MD, Daniel Guillaume, MD, Ahmed Elbermawy, MD, AndrewKeywords
This publication has 14 references indexed in Scilit:
- Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with SelumetinibCurrent Oncology Reports, 2021
- Pediatric Brain Tumors: Descriptive Epidemiology, Risk Factors, and Future DirectionsCancer Epidemiology, Biomarkers & Prevention, 2021
- Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz NeoplasmsJournal of Investigative Dermatology, 2020
- Central nervous system ganglioneuroblastoma harboring MYO5A-NTRK3 fusionBrain Tumor Pathology, 2020
- Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade GliomasCancer Cell, 2020
- Pediatric low-grade glioma in the era of molecular diagnosticsActa Neuropathologica Communications, 2020
- Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialThe Lancet Oncology, 2019
- BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the CerebellumJournal of Neuropathology & Experimental Neurology, 2015
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade GliomasNew England Journal of Medicine, 2015
- Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium ReviewCancer Epidemiology, Biomarkers & Prevention, 2014